Psoriasis gene study for Egyptian patients
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at a specific gene (Card14) in Egyptian patients with psoriasis or psoriatic arthritis. It may help understand why some people get these conditions and how they could be treated better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have psoriasis that covers more than 10% of your body or is moderate to severe.
- You may or may not have psoriatic arthritis.
- You do not have other autoimmune diseases like rheumatoid arthritis or lupus.
- You are not pregnant or breastfeeding.
- You are not currently taking medicines that suppress your immune system or strong systemic treatments.
- You do not have serious liver or kidney problems, an allergy to methotrexate, or active infections like tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This study looks at how psoriatic arthritis affects your daily life and how that relates to the severity of your condition. It aims to better understand the disease to improve future care.
This study looks at people with early arthritis related to rheumatoid arthritis, psoriatic arthritis, or psoriasis. Researchers want to understand how these early conditions behave and may help guide better treatment decisions.
This study looks at a specific genetic marker (HLA B leader) in people with psoriatic arthritis compared to healthy individuals. It may help researchers understand how this gene affects the disease.
This study looks at a genetic marker (IL-12B) in people with severe psoriasis and psoriatic arthritis who are already on Humira. It may help understand why some people respond better to treatment.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.